Lilly licensed orforglipron, now approved as Foundayo, from Chugai in 2018
The pill Lilly now sells as Foundayo began as a licensed molecule from Chugai, and its US approval adds an oral GLP-1 option for obesity alongside injections.
Eli Lilly licensed orforglipron, the compound now sold in the United States as the obesity pill Foundayo, from Chugai Pharmaceutical Co., Ltd. of Japan in 2018, according to the company's announcement of the drug's FDA approval [1]. The attribution appears in the About section of that announcement, which describes orforglipron as a once-daily small molecule (non-peptide) oral glucagon-like peptide-1 receptor agonist [1].
The license was an early step. On April 1, 2026, the FDA approved Foundayo (orforglipron) for adults with obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep it off, used with a reduced-calorie diet and increased physical activity [1]. Lilly said prescriptions were being accepted immediately, with shipping beginning April 6, followed shortly after by broad availability through US retail pharmacies and telehealth providers [1].
The clinical results cited in the approval announcement come from the ATTAIN program. In ATTAIN-1, a 72-week randomized, double-blind, placebo-controlled trial that enrolled 3,127 participants, people taking the highest dose of Foundayo who stayed on treatment lost an average of 27.3 pounds (12.4%), compared with 2.2 pounds (0.9%) for placebo [1]. Counting all participants regardless of whether they completed the trial, those taking Foundayo lost an average of 25 pounds (11.1%), compared with 5.3 pounds (2.1%) for placebo [1]. The ATTAIN program overall enrolled more than 4,500 people with obesity or overweight across two global registration trials; ATTAIN-2, which studied adults with obesity or overweight and type 2 diabetes, randomized more than 1,600 participants [1].
Lilly said the drug is designed to be taken any time of day without restrictions on food and water intake [1]. The company also said it has submitted orforglipron for weight management and/or type 2 diabetes in more than 40 countries and plans to launch in each country shortly after approval [1]. The financial terms of the 2018 Chugai license have not been disclosed in the approval announcement [1].
Why it matters for patients
Most GLP-1 obesity medicines in the US are injections. Foundayo is an oral option, and it is the only GLP-1 pill for weight loss that Lilly says can be taken any time of day without food or water restrictions [1]. That may matter to people who want to avoid injections or who have been told to time other oral GLP-1 products around meals and fluids.
Cost and access are also addressed in the announcement. Eligible people with commercial insurance may pay as little as $25 per month using the Foundayo savings card, while self-pay starts at $149 per month for the lowest dose [1]. Eligible Medicare Part D beneficiaries may be able to get it for $50 per month beginning as soon as July 1, 2026 [1].
The approval comes with limits. Foundayo is not recommended for use with other GLP-1 receptor agonist medicines, and it is not known whether it is safe and effective in children [1]. The label warns that the drug may cause tumors in the thyroid, including thyroid cancer, and lists pancreatitis, severe stomach problems, dehydration leading to kidney problems, low blood sugar, serious allergic reactions, gallbladder problems, vision changes in patients with type 2 diabetes, and food or liquid entering the lungs during surgery among possible serious side effects [1]. The most common side effects reported include nausea, constipation, diarrhea, vomiting, indigestion, stomach pain, headache, swollen belly, tiredness, belching, heartburn, gas and hair loss [1].
What happens next
Lilly has said shipping starts April 6, 2026, with wider retail and telehealth availability afterward [1]. Medicare Part D coverage at $50 per month could begin as soon as July 1, 2026 [1]. Beyond weight management, orforglipron is being studied as a potential treatment for type 2 diabetes, obstructive sleep apnea, osteoarthritis knee pain, hypertension, peripheral artery disease and stress urinary incontinence [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.